Grufity logo
Grufity logo
RZLT

RZLT - Rezolute, Inc. Stock Price, Fair Value and News

$4.57+0.24 (+5.54%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

20/100

RZLT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

RZLT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RZLT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RZLT Price Action

Last 7 days

6.4%

Last 30 days

29.9%

Last 90 days

69.5%

Trailing 12 Months

3.3%

RZLT RSI Chart

RZLT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RZLT Valuation

Market Cap

416.9M

Price/Earnings (Trailing)

-5.12

Price/Sales (Trailing)

72.27

Price/Free Cashflow

-5.67

RZLT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RZLT Fundamentals

RZLT Revenue

Revenue (TTM)

5.8M

Rev. Growth (Yr)

7.17%

Rev. Growth (Qtr)

-17.42%

RZLT Earnings

Earnings (TTM)

-81.5M

Earnings Growth (Yr)

14.5%

Earnings Growth (Qtr)

28.99%

RZLT Profitability

Return on Equity

-69.73%

Return on Assets

-64.94%

Free Cashflow Yield

-17.63%

RZLT Investor Care

Shares Dilution (1Y)

59.05%

Diluted EPS (TTM)

-0.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20265.8M---
20255.1M5.5M5.6M5.7M
20245.3M4.9M5.0M5.1M
20232.8M4.2M5.2M5.7M
202218.0K81.0K480.0K1.3M
202194.3K63.0K-73.0K
2020232.0K188.0K156.8K125.5K
2019367.6K456.0K447.0K214.0K
2018-102.3K190.7K279.1K
201413.8K---
2013117.7K106.0K92.6K24.0K
201233.7K60.2K86.8K113.3K
2011---7.1K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Rezolute, Inc.

RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
 CEO
 WEBSITErezolutebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES47

Rezolute, Inc. Frequently Asked Questions

RZLT is the stock ticker symbol of Rezolute, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Rezolute, Inc. is 416.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, RZLT's PE ratio (Price to Earnings) is -5.12 and Price to Sales (PS) ratio is 72.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RZLT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Rezolute, Inc. has provided -0.204 (multiply by 100 for percentage) rate of return.